Appeal No. 1997-1842
Application 08/068,878
predominately "1. Dunzendorfer, page 1289, column 1, lines 13-16. Lepor et al. 1988,
page 26, lines 5-7.
7. Several clinical trials in Europe have demonstrated that alpha-adrenergic
blockers are safe and effective for the treatment of symptomatic BPH. The efficacy of
alpha-blockers was usually based upon improvement in urinary flow rates and reduction
in urinary frequency. Lepor et al. 1989, page 392, column 2, first paragraph.
8. Lepor et al. 1988 demonstrated that terazosin, a well-known hypertension
medication, is a very selective "1- adrenergic blocker in the human prostate. Lepor
et al. 1988, page 25, column 1, third full paragraph, and Figure 4.
9. Dunzendorfer discloses that terazosin has been shown to be safe and
effective given once a day in the treatment of patients with mild to moderate
hypertension. Dunzendorfer, page 1289, column 2, lines 11-14.
10. Lepor et al. 1989 discloses that the primary advantage of terazosin
(HYTRIN®1) over other available alpha-adrenergic blockers, such as prazosin, is that
its longer half-life allows for a once-daily dose. Lepor et al. 1989, page 393, column 1,
lines 2-7.
1The compound sold under the trademark HYTRIN® is identified as terazosin
hydrochloride, i.e., 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-
furanyl)carbonyl]-piperazine, monohydrochloride, dihydrate. See HYTRIN®. This is
the compound recited in claims 2, 4 and 6.
8
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007